文献速递慢性肾脏病遗传性与小管间质肾病肾血管病与高血压

经导管肾去交感神经术治疗慢性严重肾脏相关疼痛

Catheter-based renal denervation as therapy for chronic severe kidney-related pain.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

本研究探索经导管肾去交感神经术(RDN)对腰痛血尿综合征(LPHS)或常染色体显性多囊肾病(ADPKD)患者疼痛及镇痛药使用的影响。11例患者接受RDN,全组疼痛视觉模拟评分(VAS)下降23 mm(P=0.012),镇痛药日限定剂量在12个月时下降但未达统计学显著。结果提示RDN可能减少疼痛及镇痛药使用,需更大样本随机对照研究验证。

要点

  • RDN可使LPHS或ADPKD患者VAS疼痛评分平均下降23 mm(P=0.012)。
  • 12个月时镇痛药日限定剂量下降,但差异无统计学意义。
  • 6个月时eGFR平均下降5.4 mL/min/1.73 m2(P=0.163),无显著差异。

核心结论

  • 经导管RDN可能减少LPHS或ADPKD患者的疼痛主诉及镇痛药使用。
  • 结果支持开展更大样本、 preferably 随机假手术对照研究。

研究设计与样本

  • 前瞻性探索性研究,纳入11例LPHS或ADPKD患者(LPHS 6例,ADPKD 5例)。
  • 纳入标准:肾脏相关疼痛≥3个月且VAS评分≥50/100。
  • 采用单电极射频消融导管行经皮RDN。
  • 观察基线至术后3、6、12个月的疼痛及镇痛药变化。

主要发现

  • 全组VAS疼痛评分下降23 mm(P=0.012)。
  • LPHS患者镇痛药日限定剂量从基线1.6(IQR 0.7-2.3)降至12个月0.3(IQR 0.0-1.9;P=0.138)。
  • ADPKD患者从基线1.4(IQR 0.0-7.4)降至12个月0.0(IQR 0.0-0.8;P=0.285)。
  • 全组6个月时eGFR平均下降5.4 mL/min/1.73 m2(P=0.163)。

临床怎么用

  • 对于LPHS或ADPKD相关的慢性严重肾脏疼痛,RDN可作为潜在微创治疗选择。
  • 需向患者说明证据来自小样本探索性研究,疗效需进一步验证。

局限性

  • 样本量小(共11例),为非随机对照研究。
  • 镇痛药剂量变化未达统计学显著。
  • eGFR下降虽无统计学意义,但需关注肾功能变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Loin pain haematuria syndrome (LPHS) and autosomal dominant polycystic kidney disease (ADPKD) are the most important non-urological conditions to cause chronic severe kidney-related pain. Multidisciplinary programmes and surgical methods have shown inconsistent results with respect to pain reduction. Percutaneous catheter-based renal denervation (RDN) could be a less invasive treatment option for these patients. METHODS: Our aim was to explore the change in perceived pain and use of analgesic medication from baseline to 3, 6 and 12 months after RDN. Patients with LPHS or ADPKD, who experienced kidney-related pain ≥3 months with a visual analogue scale (VAS) score ≥ 50/100 could be included. Percutaneous RDN was performed with a single-electrode radiofrequency ablation catheter. RESULTS: RDN was performed in 11 patients (6 with LPHS and 5 with ADPKD). Perceived pain declined in the whole group by 23 mm (P = 0.012 for the total group). In patients with LPHS and ADPKD, the median daily defined dosage of analgesic medication decreased from 1.6 [interquartile range (IQR) 0.7-2.3] and 1.4 (IQR 0.0-7.4) at baseline to 0.3 (IQR 0.0-1.9; P = 0.138) and 0.0 (IQR 0.0-0.8; P = 0.285) at 12 months, respectively. Mean estimated glomerular filtration rate decreased in the whole group by 5.4 mL/min/1.73 m2 at 6 months compared with baseline (P = 0.163). CONCLUSIONS: These results suggest that percutaneous catheter-based RDN reduces pain complaints and the use of analgesic medication in patients with LPHS or ADPKD. The present results can serve as the rationale for a larger, preferably randomized (sham) controlled study.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. de Jager RL, Casteleijn NF, de Beus E, et al. Catheter-based renal denervation as therapy for chronic severe kidney-related pain. Nephrol Dial Transplant. 2018. PMID: 28645206. doi:10.1093/ndt/gfx086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。